BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 14633274)

  • 1. Systematic reviews: a cross-sectional study of location and citation counts.
    Montori VM; Wilczynski NL; Morgan D; Haynes RB;
    BMC Med; 2003 Nov; 1():2. PubMed ID: 14633274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bibliometrics of systematic reviews: analysis of citation rates and journal impact factors.
    Royle P; Kandala NB; Barnard K; Waugh N
    Syst Rev; 2013 Sep; 2():74. PubMed ID: 24028376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cochrane systematic reviews and co-publication: dissemination of evidence on interventions for ophthalmic conditions.
    Wang X; Hawkins BS; Dickersin K
    Syst Rev; 2015 Sep; 4():118. PubMed ID: 26395078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report.
    Clarke M; Hopewell S; Chalmers I
    J R Soc Med; 2007 Apr; 100(4):187-90. PubMed ID: 17404342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bibliometric analysis of nursing education reviews.
    Oermann MH; Bailey HE; Carter-Templeton H; Condy C; Wrigley J; Ledbetter LS
    Nurse Educ Today; 2024 Aug; 139():106217. PubMed ID: 38676961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Background styles in systematic review articles are not related to the publication in high-impact-factor journals: A meta-epidemiological study.
    Kataoka Y; Taito S; Yamamoto-Kataoka S; Tsujimoto Y; Yamazaki H; Furukawa TA
    Medicine (Baltimore); 2020 Dec; 99(51):e23801. PubMed ID: 33371154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citations for Randomized Controlled Trials in Sepsis Literature: The Halo Effect Caused by Journal Impact Factor.
    Zhang Z; Poucke SV
    PLoS One; 2017; 12(1):e0169398. PubMed ID: 28046105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of Cochrane and non-Cochrane reviews over three decades.
    Andersen MZ; Zeinert P; Rosenberg J; Fonnes S
    Syst Rev; 2024 May; 13(1):120. PubMed ID: 38698429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motivating authors to update systematic reviews: practical strategies from a behavioural science perspective.
    Ervin AM
    Paediatr Perinat Epidemiol; 2008 Jan; 22 Suppl 1(0 1):33-7. PubMed ID: 18237350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of citation tracking in updating of systematic reviews.
    Choong MK; Tsafnat G
    AMIA Jt Summits Transl Sci Proc; 2014; 2014():18. PubMed ID: 25954571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
    Polansky H; Lori G
    J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.
    Polansky H; Javaherian A; Itzkovitz E
    J Evid Based Integr Med; 2018; 23():2515690X18806269. PubMed ID: 30362389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir.
    Polansky H; Javaherian A; Itzkovitz E
    Drug Des Devel Ther; 2016; 10():2713-22. PubMed ID: 27621592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How latent viruses cause breast cancer: An explanation based on the microcompetition model.
    Polansky H; Schwab H
    Bosn J Basic Med Sci; 2019 Aug; 19(3):221-226. PubMed ID: 30579323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.
    Polansky H; Itzkovitz E; Javaherian A
    Drug Des Devel Ther; 2017; 11():575-583. PubMed ID: 28424535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.
    Polansky H; Itzkovitz E; Javaherian A
    Clin Transl Med; 2016 Dec; 5(1):40. PubMed ID: 27766602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male-pattern baldness, common latent viruses, and microcompetition.
    Polansky H; Kestenbaum EH
    J Cosmet Dermatol; 2018 Dec; 17(6):1286-1287. PubMed ID: 30019525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection.
    Polansky H; Lori G
    Int J Antimicrob Agents; 2020 Jun; 55(6):105971. PubMed ID: 32283177
    [No Abstract]   [Full Text] [Related]  

  • 19. Copy number of latent viruses, oncogenicity, and the microcompetition model.
    Polansky H; Schwab H
    Oncotarget; 2018 Aug; 9(60):31568-31569. PubMed ID: 30167078
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
    Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.